Individualized automated planning for dose bath reduction in robotic radiosurgery for benign tumors.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 09 08 2018
accepted: 19 12 2018
entrez: 7 2 2019
pubmed: 7 2 2019
medline: 30 10 2019
Statut: epublish

Résumé

To explore the use of automated planning in robotic radiosurgery of benign vestibular schwannoma (VS) tumors for dose reduction outside the planning target volume (PTV) to potentially reduce risk of secondary tumor induction. A system for automated planning (AUTOplans) for VS patients was set up. The goal of AUTO- planning was to reduce the dose bath, including the occurrence of high dose spikes leaking from the PTV into normal tissues, without worsening PTV coverage, OAR doses, or treatment time. For 20 VS patients treated with 1x12 Gy, the AUTOplan was compared with the plan generated with conventional, manual trial-and-error planning (MANplan). With equal PTV coverage, AUTOplans showed clinically negligible differences with MANplans in OAR sparing (largest mean difference for all OARs: ΔD2% = 0.2 Gy). AUTOplan dose distributions were more compact: mean/maximum reductions of 23.6/53.8% and 9.6/28.5% in patient volumes receiving more than 1 or 6 Gy, respectively (p<0.001). AUTOplans also showed smaller dose spikes with mean/maximum reductions of 22.8/37.2% and 14.2/40.4% in D2% for shells at 1 and 7 cm distance from the PTV, respectively (p<0.001). Automated planning for benign VS tumors highly outperformed manual planning with respect to the dose bath outside the PTV, without deteriorating PTV coverage or OAR sparing, or significantly increasing treatment time.

Identifiants

pubmed: 30726214
doi: 10.1371/journal.pone.0210279
pii: PONE-D-18-22491
pmc: PMC6364873
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0210279

Déclaration de conflit d'intérêts

This work was in part funded by a research grant of Accuray Inc, Sunnyvale, USA. There are no patents, products in development or marketed products associated with this research to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Références

Radiat Oncol. 2015 Apr 01;10:75
pubmed: 25885689
Radiother Oncol. 2015 Mar;114(3):395-401
pubmed: 25725503
Phys Med. 2018 Feb;46:1-6
pubmed: 29519394
Radiat Oncol. 2017 Oct 2;12(1):161
pubmed: 28969706
Radiother Oncol. 2013 Feb;106(2):192-7
pubmed: 22884842
Acta Oncol. 2017 Nov;56(11):1495-1500
pubmed: 28840767
Pediatr Neurosci. 1989;15(4):176-80
pubmed: 2485912
Acta Oncol. 2018 Nov;57(11):1490-1498
pubmed: 29966472
Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):985-97
pubmed: 21353158
Acta Neurochir (Wien). 1998;140(8):763-70
pubmed: 9810442
Neurosurgery. 1997 Feb;40(2):248-60; discussion 260-2
pubmed: 9007856
Med Phys. 2016 Apr;43(4):1818
pubmed: 27036579
Acta Oncol. 2019 Jan;58(1):95-104
pubmed: 30280626
Med Phys. 2008 May;35(5):2094-103
pubmed: 18561685
Cancer Manag Res. 2018 Sep 20;10:3733-3740
pubmed: 30288104
J Neurooncol. 2012 Feb;106(3):637-42
pubmed: 21892741
Phys Med Biol. 2017 Jul 06;62(15):5926-5944
pubmed: 28486217
Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1175-9
pubmed: 24529714
J Natl Cancer Inst. 2009 Jul 1;101(13):946-58
pubmed: 19535780
Int J Radiat Oncol Biol Phys. 2018 Oct 1;102(2):443-450
pubmed: 30191874
J Neurosurg. 2016 Dec;125(Suppl 1):64-72
pubmed: 27903183
N Engl J Med. 1988 Oct 20;319(16):1033-9
pubmed: 3173432
Phys Med Biol. 2009 Sep 21;54(18):5359-80
pubmed: 19687567
J Appl Clin Med Phys. 2014 Jan 06;15(1):4530
pubmed: 24423853
Br J Radiol. 2014 Nov;87(1043):20140362
pubmed: 25226047
Neurosurg Rev. 2011 Jul;34(3):265-77; discussion 277-9
pubmed: 21305333
Med Phys. 2012 Feb;39(2):951-63
pubmed: 22320804
J Clin Endocrinol Metab. 2005 Feb;90(2):800-4
pubmed: 15562021
J Appl Clin Med Phys. 2015 Nov 08;16(6):3-16
pubmed: 26699547
Med Phys. 2014 Jun;41(6):061711
pubmed: 24877806
Radiother Oncol. 2008 Nov;89(2):180-91
pubmed: 18692929
PLoS One. 2018 Apr 26;13(4):e0196664
pubmed: 29698471
Phys Med Biol. 2012 Sep 7;57(17):5441-58
pubmed: 22864234

Auteurs

Linda Rossi (L)

Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Alejandra Méndez Romero (A)

Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Maaike Milder (M)

Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Erik de Klerck (E)

Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Sebastiaan Breedveld (S)

Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Ben Heijmen (B)

Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH